E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Primary and secondary peritoneal malignancies |
Tumeurs primaires et secondaires du péritoine |
|
E.1.1.1 | Medical condition in easily understood language |
peritoneal malignancies |
Tumeurs du péritoine |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10068069 |
E.1.2 | Term | Peritoneal carcinomatosis |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10080244 |
E.1.2 | Term | Peritoneal cancer index |
E.1.2 | System Organ Class | 10022891 - Investigations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the efficacy of pasireotide in the reduction of clinically relevant postoperative digestive leakage after CRS plus HIPEC compared to placebo |
|
E.2.2 | Secondary objectives of the trial |
Compare between the two arms: 1. secretion-absorption digestive balance 2. postoperative outcomes 3. overall and disease-free survival 4. safety profile and feasibility of treatment
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Male or female patients aged 18 years or greater • ECOG (Eastern Cooperative Oncology Group) Performance Status ≤ 2 • Primary (pseudomyxoma peritonei, peritoneal mesothelioma) or Secondary (colorectal or ovarian) peritoneal malignancies • Curative intent resection obtained by a complete resection according to the Completeness of Cytoreduction score (CC) (CC 0-1) followed by HIPEC Different intraperitoneal drug administration modalities such as neoadjuvant systemic plus simultaneous intraperitoneal and intravenous chemotherapy (NIPS) or pressurized intra-peritoneal aerosol chemotherapy (PIPAC) does not represent exclusion criteria. • Absence of extra-peritoneal metastatic disease or limited hepatic or lung metastases easily amenable to curative-intent resection or ablation • Intraoperative Peritoneal Cancer Index (PCI score) ≥ 10 • Visceral resection with at least one digestive anastomosis with or without loop ileostomy or pancreatic or biliary resection • Negative serum pregnancy test for women of childbearing potential within 7 days prior to therapy • Sexually active women of childbearing potential must agree to use a highly effective method of contraception or to abstain from sexual activity during the study and for 3 months after the last study treatment administration. Sexually active males patients must agree to use condom or to abstain from sexual activity during the study and for 3 months after the last study treatment administration. Also, it is recommended their women of childbearing potential partner use a highly effective method of contraception • Patient should understand, sign, and date the written informed consent form prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol. • Patients must be affiliated to a social security system or beneficiary of the same
|
|
E.4 | Principal exclusion criteria |
• Macroscopically incomplete surgical resection (CC 2) • Standard contraindications to pasireotide: - patients with uncontrolled diabetes mellitus or a fasting plasma glucose > 250mg/dl (14 mMol/L) - patients who have congestive heart failure (NYHA Class III or IV), unstable angina, sustained ventricular tachycardia, ventricular fibrillation, clinically significant bradycardia including a corrected QT (QTc) interval longer than 450 msec, advanced heart block or a history of acute myocardial infarction within the six months preceding enrollment - patients with liver disease such as severe hepatic impairment (Child Pugh C), chronic active hepatitis or chronic persistent hepatitis with abnormal coagulation (INR>1.5). - patients with the presence of active or suspected acute or chronic uncontrolled infection - hypersensitivity to somatostatin analogues or any component of pasireotide formulations - patients with uncontrolled hypothyroidism • Patients participating or who have participated to another study evaluating the effect of a new drug other than pasireotide within 1 month prior to dosing • Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable or will be unable to complete the entire study. • Women who are pregnant or likely to be so, or who are breastfeeding • Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The rate of clinically relevant (NCI CTCAE v5 ≥ grade 3) postoperative digestive leakage at 97 days |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
90 days after the end of treatment (=J97) |
|
E.5.2 | Secondary end point(s) |
• Nasogastric output, duration of postoperative ileus, early functional results • Overall and severe complication, length of hospital stay • Overall and disease-free survivals • Safety and feasibility
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
During Long-Term follow up : in maximum 3 years.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |